

# INVITATION

## 6 November 2024

# The role of ECP in CTCL management

Hospital Clínico Valencia, instalaciones nuevas Incliva

This information is intended for healthcare professionals in Europe

## Agenda

**Time: 08:00 – 09:05**

- 
- |               |   |
|---------------|---|
| 08:00 – 08:30 | <b>Durability of Response – An important parameter in the management of CTCL</b><br>Prof. Pietro Quaglino, University of Turin, Italy |
| 08:30 – 08:45 | <b>Presenting complicated case – Role ECP in CTCL</b><br>Dr. Montserrat Gomez, Hospital Clínico Universitario de Valencia, Spain      |
| 08:45 – 09:00 | <b>Presenting complicated case – How do you manage this?</b><br>Dr. Ana Saus, Hospital Clínico Universitario de Valencia, Spain       |
| 09:00 – 09:05 | <b>Q&amp;A</b><br>All   |

*ECP: Extracorporeal Photopheresis, CTCL: Cutaneous T-cell Lymphoma*

*All speakers are subject to contract.*

***This is a commercial programme run by Therakos (UK) Ltd,  
a Mallinckrodt Company.***

[Privacy policy](#)

Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2024 Mallinckrodt. ES-2400024 September 2024.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.*